ERLEADA® (apalutamide)

 

As soon as your patients are diagnosed with mCSPC or non-metastatic CRPC…

Push Back
on Progression

Start early with ERLEADA®

as soon as your patients are diagnosed with mCSPC or non-metastatic CRPC*

Metastatic castration-sensitive prostate cancer (mCSPC)

ERLEADA® + ADT reduced the risk of death by % vs placebo + ADT1

(Median overall survival was not estimable in either arm; HR=0.67; 95% CI: 0.51, 0.89; P=0.0053)

Learn more about the TITAN study:

Non-metastatic castration-resistant prostate cancer (nmCRPC)

ERLEADA® + ADT improved median metastasis-free survival (MFS) by 2 YEARS (24.3 months) vs placebo + ADT1

(40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)

Learn more about the SPARTAN study:

TITAN Publication

Learn more about the results of the TITAN study by reviewing the article published in The New England Journal of Medicine.

SPARTAN Primary Publication

Learn more about the results of the SPARTAN study by reviewing the article published in The New England Journal of Medicine.

Exploratory Analysis

SPARTAN Patient-Reported Outcomes Publication

Find out about patient-reported outcomes in the SPARTAN study by reviewing the article published in The Lancet Oncology.

The articles above may only be available to subscribers of the respective journals. To access this content, you may have to sign in using your personal or institutional credentials. If you are not registered or a member of these journals, then you may need to purchase the articles through their sites.

Your One Source for Access, Affordability, and Treatment Support for Your Patients

Call a Janssen CarePath Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET.

*All patients who enrolled in the TITAN study started ADT for mCSPC ≤6 months prior to randomization.2

In the SPARTAN study, conventional imaging (technetium-99m bone scans and CT scans) was used to confirm that patients were non-metastatic at screening for inclusion. Patients with pelvic lymph nodes <2 cm in short axis (N1) located below the iliac bifurcation at screening were allowed in the study. All patients in SPARTAN had a PSA doubling time ≤10 months at study entry.1,3

ADT = androgen deprivation therapy; CI = confidence interval; CRPC = castration-resistant prostate cancer; CT = computed tomography; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; nmCRPC = non-metastatic castration-resistant prostate cancer; PSA = prostate-specific antigen; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.

References

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

2. Chi KN, Agarwal N, Bjartell A, et al; for the TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.

3. Smith MR, Saad F, Chowdhury S, et al; for the SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418.